Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study

• This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
• Lexaria has received approval from the Independent Review Board for its DehydraTECH-CBD Human Clinical HYPER-H21-4 study.
• The approval signals the company has taken the appropriate steps to protect the rights and welfare of human subjects participating in its fourth human study
• HYPER-H21-4 should “de-risk” outcomes prior to Lexaria’s planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat hypertension and perhaps other forms of cardiovascular disease
• Previous studies – HYPER-H21-1 and HYPER-H21-2 – have evidenced a remarkable, rapid, and safe drop in blood pressure with DehydraTECH-CBD

A little less than two months after Lexaria Bioscience LEXX announced it was readying the study protocols for HYPER-H21-4, its most ambitious and comprehensive study yet, for submission to the Independent Review Board (“IRB”) with approval anticipated by January 2022 (https://cnw.fm/xCGhl), the company is celebrating the receipt of the approval ahead of schedule. 

An administrative body created to safeguard the rights and welfare of human subjects recruited to participate in research activities, the IRB is tasked with…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWire: Text “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

Image sourced from Pixabay

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.